Condition: Unresectable or Metastatic Advanced Solid Tumors · Sponsor: Zhejiang University
This trial is a multi-center, open-label investigator-initiated clinical study (IIT) to evaluate the safety, pharmacokinetics, pharmacodynamics and effectiveness of WTX212A injection in the treatment of patients with unresectable or metastatic advanced solid tumors who failed in previous systematic therapy. The study was divided into two phases: dose escalation and dose expansion
This description comes directly from the study's public registry record.
Qi Zhang, M.D. · 13858108798 · qi.zhang@zju.edu.cn
Qihan Fu, M.D. · ayfuqihan@126.com
Always discuss trial participation with your own doctor first.
| the First Affiliated Hospital, School of Medicine, Zhejiang University | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06026605